Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
The first participant has been enrolled in a Phase 2 clinical trial testing AC-203 for the treatment of inherited epidermolysis bullosa (EB), the trial’s sponsor, TWi Biotechnology, announced. AC-203 (also ... Read more
U.S. residents with some types of inherited epidermolysis bullosa (EB) can now participate in Amryt Pharma‘s Phase 3 trial testing AP101 (Oleogel-S10), an experimental treatment for EB. This comes in ... Read more
The U.S. Food and Drug Administration has cleared Krystal Biotech‘s investigational new drug application for KB103, a topical gene therapy for dystrophic epidermolysis bullosa (DEB). The company can now start ... Read more
Researchers found two mutations in a gene that carries the instructions for the protein plectin in a patient with epidermolysis bullosa simplex (EBS). Plectin helps maintain the integrity of the skin, ... Read more
Orphan Drug Designation was recently granted to ProQR Therapeutics’ investigational therapy QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB) by the European Medicines Agency (EMA). Orphan Drug Designation ... Read more
Cannabinoid therapy developer InMed and French tissue engineering company ATERA have teamed up to develop 3-D human skin models with tissue taken from epidermolysis bullosa (EB) patients. The models ... Read more
The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory ... Read more